8-K: Citius Pharmaceuticals Secures $3 Million in Registered Direct Offering

Citius Pharmaceuticals has successfully completed a registered direct offering, raising $3 million through the sale of common stock and warrants.

Summary

• Citius Pharmaceuticals entered into a securities purchase agreement on November 15, 2024, with institutional investors for a registered direct offering.
• The offering included 12,000,000 shares of common stock and warrants to purchase an additional 12,000,000 shares.
• The combined offering price for one share and one warrant was $0.25.
• The warrants are exercisable immediately at $0.25 per share and expire five years after the initial exercise date.
• H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
• Citius agreed to pay Wainwright a cash fee of 7.0% of the gross proceeds, plus reimbursements for legal counsel, non-accountable expenses, and a clearing fee.
• Placement agent warrants to purchase 840,000 shares at $0.3125 per share were also granted to Wainwright.
• The net proceeds to Citius from the offering were approximately $2.7 million after deducting fees and expenses.
• The company intends to use the net proceeds for general corporate purposes, including pre-clinical and clinical development, working capital, and capital expenditures.
• Citius agreed not to issue or announce the issuance of additional shares or convertible securities for 30 days following the closing, with some exceptions.
• For one year, Citius agreed not to issue equity or debt securities with floating conversion prices or enter into agreements for future-determined price issuances, with some exceptions.
• The offering was made under an effective registration statement from March 1, 2024, with a prospectus supplement filed on November 18, 2024.
• The offering closed on November 18, 2024.

Sentiment

Score: 7

Explanation: The document is generally positive as it details a successful capital raise, but there are some restrictions on future financing that could be seen as a slight negative. The company is moving forward with its development plans.

Positives

• The company successfully raised $3 million in funding.
• The funds will support the development of the company's product pipeline.
• The offering was completed quickly, closing on November 18, 2024.
• The company has secured funding for general corporate purposes, including working capital.

Negatives

• The company is restricted from issuing new shares or convertible securities for 30 days, which could limit flexibility.
• The company is restricted from issuing floating-price securities for one year, which could limit future financing options.
• The company paid a 7% cash fee to the placement agent, plus additional expenses, reducing the net proceeds.

Risks

• The company is restricted from issuing new shares or convertible securities for 30 days, which could limit flexibility.
• The company is restricted from issuing floating-price securities for one year, which could limit future financing options.
• The company's future success depends on the clinical development of its product candidates.
• The company's ability to raise additional capital in the future is not guaranteed.

Future Outlook

The company intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of its product candidates and working capital and capital expenditures.

Management Comments

• The company currently intends to use the net proceeds from the offering for general corporate purposes, including pre-clinical and clinical development of our product candidates and working capital and capital expenditures.

Industry Context

This capital raise is typical for a biopharmaceutical company in the clinical development stage, as they often require significant funding to advance their product pipeline. The company's focus on critical care products aligns with the growing demand for innovative treatments in this sector.

Comparison to Industry Standards

• The offering structure, including the use of warrants, is a common practice in the biotech industry for raising capital.
• The 7% placement agent fee is within the typical range for similar offerings.
• The use of a registered direct offering allows for a quicker capital raise compared to a traditional underwritten offering.
• The restrictions on future issuances are standard to protect investors from dilution.
• Comparable companies such as Xencor, Inc. and Arcus Biosciences, Inc. have also used similar financing methods to fund their clinical programs.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees will benefit from the continued funding of operations and development programs.
• Customers may benefit from the development of new critical care products.
• Suppliers and creditors will be paid as the company continues to operate.

Next Steps

• The company will use the net proceeds for general corporate purposes, including pre-clinical and clinical development.
• The company will continue to engage with the FDA regarding its product candidates.
• The company will work to maintain its listing on the Nasdaq Capital Market.

Key Dates

Keywords

registered direct offering, common stock, warrants, biopharmaceutical, clinical development, capital raise, placement agent, financing, healthcare, CTXR